Home

Mark Stenhouse

CIK 1734751 · Chief Operating Officer · last filed 2026-05-21

Mark Stenhouse is a Chief Operating Officer who has filed 19 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing, for PHAT, was dated May 21, 2026. Across all open-market trades the lifetime net is −$1.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $453.0K across reported positions. 8 SEC filings were submitted jointly with EXACT SCIENCES CORP.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$453.0K

Companies

3

Total Filings

19

Lifetime Open-Market Net

-$1.53M

Filer Profile

Reported Address
5505 ENDEAVOR LANE
MADISON, WI 53719
Related Filers
EXACT SCIENCES CORP — 8 joint filings, latest 2020-04-06
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PHAT Director 54,122 $8.37 $453.0K $0 7 2026-05-21
Prometheus Biosciences, Inc. (RXDX) Delisted Chief Operating Officer 0 $199.92 $0 $266.0K 6 2023-06-16
EXACT SCIENCES CORP (EXAS) Delisted President, Cologuard 41,874 $104.91 $4.39M -$1.80M 6 2020-04-06

Recent Filings

19 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-21 PHAT Grant (A) +24,122 $0 EDGAR
2025-06-05 PHAT Grant (A) +10,500 $0 EDGAR
2024-05-24 PHAT Grant (A) +10,500 $0 EDGAR
2023-06-16 Prometheus Biosciences, Inc. (RXDX) Delisted Disp (D) −26,754 $0 EDGAR
2023-06-02 Prometheus Biosciences, Inc. (RXDX) Delisted Other (J) — $0 EDGAR
2023-05-30 PHAT Grant (A) +9,000 $0 EDGAR
2022-12-13 Prometheus Biosciences, Inc. (RXDX) Delisted Grant (A) +9,811 $0 EDGAR
2022-05-27 PHAT Grant (A) — $0 EDGAR
2022-05-20 Prometheus Biosciences, Inc. (RXDX) Delisted Grant (A) — $0 EDGAR
2021-11-16 Prometheus Biosciences, Inc. (RXDX) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 19
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.